Showing 5761-5770 of 6768 results for "".
- Sunscreen Chemicals Found in the Bloodstream: Experts React to the New Findingshttps://practicaldermatology.com/news/sunscreen-chemicals-found-in-bloodstream-experts-react-to-the-new-findings/2460023/Several active ingredients found in different sunscreens enter the bloodstream at levels that far exceed the FDA's recommended threshold without a government safety inspection, a new study in Journal of the American M
- Aesthetic Innovations Summit Coming to New Orleanshttps://practicaldermatology.com/news/aesthetic-innovations-summit-coming-to-new-orleans/2460022/Coming off an impressive inaugural meeting in 2018, the second annual Aesthetics Innovation Summit will unite over 300 of the most influential corporate, capital, and clinical leaders in New Orleans to collaborate on the development and adoption of new aesthetic treatments and technologies.
- ISHRS Awareness Campaign Takes on Black Market Hair Restoration Clinicshttps://practicaldermatology.com/news/ishrs-awareness-campaign-takes-on-black-market-hair-restoration-clinics/2460016/The International Society of Hair Restoration Surgery (ISHRS) is launching a new public awareness campaign to help patients recognize “black market pirate” hair restoration clinics and misleading advertising claims. Social media engagement will be the cornerstone of the new
- Happy 10th Birthday Dysport!https://practicaldermatology.com/news/happy-10th-birthday-dysport/2460015/Galderma Laboratories’ Dysport (abobotulinumtoxinA) is ringing in its 10th birthday. To celebrate this milestone, Galderma is offering double points for Dysport aesthetic treatments registered in the ASPIRE Rewards program through July 31
- Xstrahl Introduces UpGraded Treatment System for Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/xstrahl-introduces-upgraded-treatment-system-for-non-melanoma-skin-cancer/2460011/Xstrahl Medical is launching its latest superficial radiotherapy treatment system to treat the full range of non-melanoma skin cancer cases. The new Xstrahl 150 system offers several features that enhance the capabilities of Xstrahl's curr
- Study Highlights Adverse Events Associated with Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/study-highlights-adverse-events-associated-with-energy-based-vaginal-rejuvenation/2460010/Concerns from the federal Food and Drug Administration (FDA) sired the first assessment of adverse events related to device-based procedures marketed for ‘vaginal rejuvenation,’ and the new analysis of the Manufacturer and User Facility Device Experience (MAUDE) database identified a
- FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-duobrii-for-treatment-of-plaque-psoriasis/2460009/The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical lotion that contains a unique combination of halobetasol prop
- Ovation Science Appoints Medical Dermatology Advisory Boardhttps://practicaldermatology.com/news/ovation-science-appoints-medical-dermatology-advisory-board/2460008/Ovation Science, Inc. has entered into an exclusive agreement with Skincareguide.com Ltd., to act as the Company's Medical Dermatology Advisory Board for cannabis formulated products. The objective of the Medical Dermatology Advisory Board is to provide guidance, along with clinical, scientif
- Brooke Shields Takes on New Role as Celebrity Spokesperson for SculpSure Body Contouringhttps://practicaldermatology.com/news/brooke-shields-take-on-new-role-as-celebrity-spokesperson-for-sculpsure-body-contouring/2460005/Actress, model, Broadway star, and author Brooke Shields will serve as national spokesperson for Hologic’s Cynosure's SculpSure body contouring laser treatment. As the face of SculpSure’s new “Be strong. Be sexy. Be confident.” campaign, Ms. Shields will inspire consum
- Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapyhttps://practicaldermatology.com/news/fibrocell-to-collaborate-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-rdeb-gene-therapy/2460004/Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disord